Who's liable for breast cancer prevention?

References

• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998;90(18):1371–88
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Collyar DE, Somerfield MR, et al. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol 1999;17(6):1939–55
   PubMedGoogle Scholar
• Physician Insurers Association of America. Breast cancer study 1995. Washington, DC: Physician Insurers Association of America, 1995
   Google Scholar
• Osuch JR, Bonham VL, Morris LL. Primary care guide to managing a breast mass: a legal perspective on risk management. Medscape Womens Health 1998;3(5):3
   PubMedGoogle Scholar
• Gump FE. Medicolegal pitfalls in the diagnosis of breast cancer. Compr Ther 1995;21(1):3–6
   PubMedGoogle Scholar
• Kern KA. Fundamental cause of carcinoma of the breast malpractice litigation. J Am Coll Surg 1994;179(4):505–8
   PubMedGoogle Scholar
• Dewar MA, Love N. Legal issues in managing breast disease. Postgrad Med 1992;92(5):137–51
   PubMed Web of Science ®Google Scholar
• Caplan LS. Liability in breast cancer screening. Trends Health Care Law Ethics 1994;9(2):35–734
   PubMedGoogle Scholar
• Brenner RJ. Breast cancer evaluation: medical- legal and risk management considerations for the clinician. Cancer 1994:74(1 Suppl):486–90
   PubMedGoogle Scholar
• Campanella PJ. Breast cancer: staging, treatment, and the duty to inform. Med Trial Technique Q 1988;35(1): 17–47
   Google Scholar
• Saxton JW. Sued for misdiagnosis? A complete, updated and signed history is vital beforehand. Med Pract Commun 1997;4(3):1–3
   Google Scholar
• Corker WR. Legal aspects of breast cancer. Trauma 1991;33(2):59–80
   Google Scholar
• Spratt JS, Spratt SW. Medical and legal implications of screening and follow-up procedures for breast cancer. Cancer 1990;66(6 Suppl): 1351–62
   PubMed Web of Science ®Google Scholar
• Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181–7
   PubMed Web of Science ®Google Scholar
• Harris JR, Lippman ME, Veronesi U, et al. Breast cancer (1). N Engl J Med 1992;327(5): 319–28
   PubMed Web of Science ®Google Scholar
• Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81(24): 1879–86
   PubMed Web of Science ®Google Scholar
• Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 1994;73(3):643–51
   PubMed Web of Science ®Google Scholar
• Coughlin SS, Khoury MJ, Steinberg KK. BRCA1 and BRCA2 gene mutations and risk of breast cancer: public health perspectives. Am J Prev Med 1999;16(2):91–8
   PubMedGoogle Scholar
• Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;56(1):265–71
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Bishop DT, et al. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994; 343(8899):692–5
   PubMed Web of Science ®Google Scholar
• Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336(20):1401–8
   PubMed Web of Science ®Google Scholar
• Thorlacius S, Struewing JP, Hartge P, et al. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 1998; 352(9137):1337–9
   PubMedGoogle Scholar
• Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000;26(4):291–302
   PubMedGoogle Scholar
• Cook MG, Rohan TE. Benign breast disease: the relationship between its histological features and risk factors for breast cancer. Pathology 1991;23(4):286–90
   PubMed Web of Science ®Google Scholar
• Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 1993;71(4):1258–65
   PubMed Web of Science ®Google Scholar
• Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312(3):146–51
   PubMed Web of Science ®Google Scholar
• Fitzgibbons PL, Henson DE, Hutter RV. Benign breast changes and the risk for subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998;122(12):1053–5
   PubMedGoogle Scholar
• Jacobs TW, Byrne C, Colditz G, et al. Radial scars in benign breast-biopsy specimens and the risk of breast cancer. N Engl J Med 1999;340(6):430–6
   PubMed Web of Science ®Google Scholar
• Jensen RA, Page DL, Dupont WD, et al. Invasive breast cancer risk in women with sclerosing adenosis. Cancer 1989;64(10):1977–83
   PubMedGoogle Scholar
• Krieger N, Hiatt RA. Risk of breast cancer after benign breast diseases: variation by histologic type, degree of atypia, age at biopsy, and length of follow-up. Am J Epidemiol 1992;35(6):619–31
   Google Scholar
• London SJ, Connolly JL, Schnitt SJ, et al. A prospective study of benign breast disease and the risk of breast cancer. JAMA 1992;267(7):941–4
   PubMed Web of Science ®Google Scholar
• McDivitt RW, Stevens JA, Lee NC, et al. Histologic types of benign breast disease and the risk for breast cancer. The Cancer and Steroid Hormone Study Group. Cancer 1992;69(6): 1408–14
   PubMedGoogle Scholar
• Roberts MM, Jones V, Elton RA, et al. Risk of breast cancer in women with history of benign disease of the breast. Br Med J 1984:288(6413): 275–8
   PubMedGoogle Scholar
• Eddy DM. Breast cancer screening. J Natl Cancer Inst 1989;81(3):234–5
   PubMedGoogle Scholar
• Madigan MP, Ziegler RG, Benichou J, et al. Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst 1995;87(22):1681–5
   PubMed Web of Science ®Google Scholar
• Baker LH. Breast Cancer Detection Demonstration Project: five-year summary report. CA Cancer J Clin 1982;32(4):194–225
   PubMedGoogle Scholar
• Bondy ML, Lustbader ED, Halabi S, et al. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst 1994;86(8):620–5
   PubMedGoogle Scholar
• Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91(18):1541–8
   PubMed Web of Science ®Google Scholar
• Spiegelman D, Colditz GA, Hunter D, et al. Validation of the Gail et al. model for predicting individual breast cancer risk. J Natl Cancer Inst 1994;86(8):600–7
   PubMedGoogle Scholar
• Claus EB, Risch NJ, Thompson WD. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 1990;131(6):961–72
   PubMed Web of Science ®Google Scholar
• Garber J. A 40-year-old woman with a strong family history of breast cancer. JAMA 1999;282(20):1953–60
   PubMedGoogle Scholar
• Black WC, Nease RF Jr, Tosteson AN. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst 1995;87(10):720–31
   PubMed Web of Science ®Google Scholar
• Bunker JP, Houghton J, Baum M. Putting the risk of breast cancer in perspective. BMJ 1998;317(7168):1307–9
   PubMedGoogle Scholar
• ACOG committee opinion. Tamoxifen and endometrial cancer. No. 169, Feb 1996. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 1996;53(2):197–9
   Google Scholar
• Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91(21):1829–46
   PubMedGoogle Scholar
• Smedira HJ. Practical issues in counseling healthy women about their breast cancer risk and use of tamoxifen citrate. Arch Intern Med 2000; 160(20):3034–42
   PubMedGoogle Scholar
• Thune I, Brenn T, Lund E, et al. Physical activity and the risk of breast cancer. N Engl J Med 1997;336(18):1269–75
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340(2):77–84
   PubMed Web of Science ®Google Scholar
• Grann VR, Panageas KS, Whang W, et al. Decision analysis of prophylactic mastectomy and oophorectomy in BRCAl-positive or BRCA2- positive patients. J Clin Oncol 1998;16(3):979–85
   PubMed Web of Science ®Google Scholar
• Schrag D, Kuntz KM, Garber JE, et al. Decision analysis—effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997;336(20):1465–71
   PubMedGoogle Scholar
• Borgen PI, Hill AD, Tran KN, et al. Patient regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 1998;5(7):603–6
   PubMedGoogle Scholar
• Eisen A, Weber BL. Prophylactic mastectomy—the price of fear. N Engl J Med 1999;340(2): 137–8
   PubMedGoogle Scholar